Sunday
August 31, 2025
8:30 AM ET
Amarin Highlights Key Data Providing Mechanistic Insights into Eicosapentaenoic Acid (EPA) at ESC 2025
Saturday
August 30, 2025
8:30 AM ET
New REDUCE-IT® Analyses Presented at ESC 2025 Include Data Showing VASCEPA®/VAZKEPA® (Icosapent Ethyl) Therapy Resulted in 9% Fewer Total Hospitalizations & Reduces Cardiovascular Disease Risk in Certain High-Risk Patient Subgroups
Monday
August 25, 2025
8:00 AM ET
New Analyses from REDUCE-IT® and EPA Mechanistic Data to be Presented at the European Society of Cardiology (ESC) Congress 2025
Wednesday
July 30, 2025
7:00 AM ET
Amarin Reports Second Quarter 2025 Financial Results
Wednesday
July 23, 2025
7:30 AM ET
Amarin to Report Second Quarter 2025 Financial Results and Host Conference Call on July 30, 2025
Tuesday
June 24, 2025
7:00 AM ET
Amarin Announces Exclusive License and Supply Agreement with Recordati to Commercialize VAZKEPA® (Icosapent Ethyl) in Europe
Wednesday
May 7, 2025
7:00 AM ET
Amarin Reports First Quarter 2025 Financial Results
Monday
April 28, 2025
4:15 PM ET
Amarin to Report First Quarter 2025 Financial Results and Host Conference Call on May 7, 2025
Wednesday
March 12, 2025
7:00 AM ET
Amarin Reports Fourth Quarter Financial Results & Business Update and Announces Important Corporate Action